Effectiveness of antifolate receptor antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages.код для вставкиСкачать
ARTHRITIS & RHEUMATISM Vol. 52, No. 9, September 2005, pp 2666–2675 DOI 10.1002/art.21228 © 2005, American College of Rheumatology Effectiveness of Anti–Folate Receptor ␤ Antibody Conjugated With Truncated Pseudomonas Exotoxin in the Targeting of Rheumatoid Arthritis Synovial Macrophages Ryusaku Nagayoshi,1 Taku Nagai,1 Kakushi Matsushita,1 Katsuaki Sato,1 Nobuhiko Sunahara,2 Takemasa Matsuda,2 Tadashi Nakamura,3 Setsuro Komiya,1 Masanori Onda,4 and Takami Matsuyama1 Objective. To define the distribution of folate receptor ␤ (FR␤)–expressing cells in various tissues, including rheumatoid arthritis (RA) synovial tissues, and to verify the effects of an immunotoxin composed of an anti-FR␤ monoclonal antibody (mAb) and truncated Pseudomonas exotoxin A (PEA) on apoptosis and tumor necrosis factor ␣ (TNF␣) production by adherent synovial mononuclear cells from RA patients. Methods. Anti-FR␤ mAb were produced by immunizing mice with FR␤-transfected murine pre–B cells. The distribution of the FR␤ antigen was examined by immunohistochemical analysis using anti-FR␤ mAb and macrophage-specific anti-CD163 mAb. Anti-FR␤ mAb was chemically crosslinked with truncated PEA. FR␤-expressing macrophages were produced by the transfection of adenovirus vector containing the FR␤ gene. Apoptotic cells were detected by staining with propidium iodide. TNF␣ was measured by enzymelinked immunosorbent assay. Results. FR␤-expressing cells were not present in peripheral blood leukocytes and their activated cells. In all of the tissues examined, most FR␤-expressing cells were CD163ⴙ. The immunotoxin significantly induced the apoptosis of FR␤-transfected macrophages and adherent RA synovial mononuclear cells and inhibited TNF␣ production by adherent RA synovial mononuclear cells. Conclusion. We demonstrated the limited distribution of FR␤-expressing cells in various tissues. The immunotoxin targeting FR␤-expressing cells will provide a therapeutic tool for rheumatoid synovitis. Activated synovial macrophages are thought to play an important role in the pathogenesis of rheumatoid arthritis (RA) (1–3). These macrophages release proinflammatory cytokines, proteinases, and other chemical mediators that lead to the development of synovitis and joint destruction. The removal of macrophages decreases the severity of joint disease in animal models of RA (4,5). Several antirheumatic drugs, including D-penicillamine and gold salts, affect synovial macrophages (6,7). Furthermore, one of the actions of anti–tumor necrosis factor ␣ (anti-TNF␣) therapy may be the result of antibody-dependent cellular cytotoxicity of membranous TNF␣-expressing macrophages (8,9). Thus, reagents that target synovial macrophages may be very effective in the treatment of RA. We have shown that folate receptor ␤ (FR␤) messenger RNA (mRNA) and protein are highly expressed by synovial macrophages, but not by other synovial cells, in the inflamed joints of patients with RA (10). In a rat arthritis model, 99mTc-labeled folate was found to specifically accumulate in affected joints (11). Moreover, we have shown that treatment with a drug that blocks FR␤ reduces disease activity in murine collagen-induced arthritis (12). Dr. Matsuyama’s work was supported by a grant-in-aid for scientific research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology. 1 Ryusaku Nagayoshi, MD, Taku Nagai, PhD, Kakushi Matsushita, MD, PhD, Katsuaki Sato, PhD, Setsuro Komiya, MD, PhD, Takami Matsuyama, MD, PhD: Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; 2Nobuhiko Sunahara, MD, PhD, Takemasa Matsuda, MD, PhD: Kagoshima Red Cross Hospital, Kagoshima, Japan; 3Tadashi Nakamura, MD, PhD: Kumamoto Orthopaedic Hospital, Kumamoto, Japan; 4Masanori Onda, MD, PhD: Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Address correspondence and reprint requests to Takami Matsuyama, MD, PhD, Department of Immunology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, Japan 890-854. E-mail: [email protected] kagoshima-u.ac.jp. Submitted for publication November 30, 2004; accepted in revised form May 16, 2005. 2666 TARGETING OF RA SYNOVIAL MONONUCLEAR CELLS WITH ANTI-FR␤ AND TRUNCATED PEA FR␤ is expressed by acute myelogenous leukemia cells (13,14). In vitro studies suggest that folate liposomes that contain cytotoxic drugs might be useful for the treatment of this disease (15). In addition, immunotoxins, which are composed of specific antibodies combined with toxins, such as Pseudomonas exotoxin A (PEA), diphtheria toxin, gelonin, saporin, and ricin A, effectively bind to malignant cells that bear the appropriate surface antigens (16,17) and monocyte/ macrophages (18–20). However, there are no reports of immunotoxins that target FR␤. Before we develop and test these immunotoxins, it is important to determine the distribution of FR␤-expressing cells in normal and inflamed tissues from humans. In the present study, we produced monoclonal antibodies (mAb) against human FR␤. We used these mAb to detect FR␤-expressing cells in a variety of tissues and cells. We then prepared an immunotoxin composed of an anti-FR␤ mAb and truncated PEA (16,17) and verified that the immunotoxin selectively targets RA synovial macrophages in vitro. MATERIALS AND METHODS Tissue samples. Synovial tissue was obtained from 10 RA patients who underwent total knee replacement surgery. These patients fulfilled the American College of Rheumatology (formerly, the American Rheumatism Association) 1987 criteria for RA (21) and had previously been treated with either methotrexate, D-penicillamine, gold salts, sulfasalazine, bucillamine, or prednisone (⬍7.5 mg/day) or combinations of these drugs. Adherent synovial mononuclear cells were prepared as previously described (22). Briefly, synovium was digested with type V collagenase (Sigma-Aldrich, St. Louis, MO) for 45 minutes at 37°C. Cell suspensions were filtered through a stainless steel mesh. Mononuclear cells were isolated on a Ficoll-Hypaque gradient, incubated in plastic plates for 1 hour at 37°C, and washed 10 times with phosphate buffered saline. These steps for obtaining adherent cells were repeated. Using the same procedures, adherent lung mononuclear cells were prepared from lung tissues obtained by surgical resection for lung carcinoma from 4 patients. Samples of skin (n ⫽ 3), lung (n ⫽ 3), liver (n ⫽ 2), spleen (n ⫽ 2), kidney (n ⫽ 1), intestine (n ⫽ 3), and lymph node (n ⫽ 3) obtained by surgical resection for cancers were used for immunohistochemistry analysis to detect FR␤expressing cells. Peripheral blood was drawn from 4 healthy donors, and synovial fluid was drawn from the swollen knee joints of 3 RA patients. Monocytes were prepared from the peripheral blood of healthy donors and were stimulated with lipopolysaccharide (LPS; derived from Escherichia coli 0111:B4) (SigmaAldrich), macrophage colony-stimulating factor (M-CSF) (Pierce, Rockford, IL), or interferon-␥ (IFN␥) (Pierce) as described previously (22). Informed consent was obtained from all donors in 2667 accordance with the requirements of the Human Investigations Committee of Kagoshima University. Production of mAb against the FR␤ antigen. Murine FR␤-expressing pre–B cells were prepared for immunogens as follows. FR␤ complementary DNA (cDNA) containing the Kozak consensus and coding sequence was prepared from a reverse transcription–polymerase chain reaction (RT-PCR) product derived from RA synovial cells, as previously described (10). The primer sequences were 5⬘-AGAAAGACATGGTCTGGAAATGGATG-3⬘ (upstream) and 5⬘GACTGAACTCAGCCAAGGAGCCAGAGTT-3⬘ (downstream). The cDNA fragment was ligated with pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA), and its identity was confirmed by sequencing. The Eco RI–digested insert was then ligated into pEF-BOS (23). This construct was transfected into B300-19 cells (murine pre–B cell line) with the use of Lipofectamine (Invitrogen). After 48 hours, transfected cells were selected in 1,000 g/ml of G-418 disulfate (Nakarai Tesque, Kyoto, Japan) in Dulbecco’s minimum essential medium (DMEM) containing 10% fetal calf serum. Resistant colonies were examined by RT-PCR using the above primers. BALB/c mice were immunized with the FR ␤ transfected B300-19 cells. Their spleen cells were fused with NS-1 myeloma cells. Hybridomas were screened for reactivity with FR␤-transfected B300-19 cells by flow cytometric and Western blot analyses. Two anti-FR␤ mAb (36b [IgG2a isotype] and 94b [IgG1 isotype]) were selected for further evaluation. Preparation of truncated PEA. Truncated PEA was purified as previously described (24). Briefly, the plasmid pMS8-38-402, which encodes the truncated LysPE38QQR protein, was transfected into BL21 (DE3) cells (Stratagene, La Jolla, CA). After induction with IPTG, periplasm was collected. Truncated PEA was purified through Poros HQ (Applied Biosystems, Foster City, CA) and TSK 3000 SW (Tosoh, Tokyo, Japan) columns using a Vision Workstation Liquid Chromatography system (Japan Perceptive, Tokyo, Japan). The activity of truncated PEA was evaluated by the Carroll method (25). Briefly, the ADP ribosylation of truncated PEA was measured using wheat germ extract containing ADP ribosyltransferase (Promega, Tokyo, Japan) and 14Clabeled nicotinamide adenine dinucleotide (Daiichikagaku, Tokyo, Japan). Preparation of immunotoxin. Anti-FR␤ immunotoxin was prepared according to a slight modification of Hassan’s procedure (24). Briefly, 1 ml of anti-FR␤ mAb (3 mg/ml) was incubated with 100 g of succinimidyl trans-4(maleimidomethyl) cyclohexane-1-carboxylate (SMCC; SigmaAldrich) for 1 hour at room temperature. One milliliter of truncated PEA (10 mg/ml) was incubated with 400 g of succinimidyl 3-(2-pyridyldithio)propionate (SPDP; SigmaAldrich) for 12 hours at 4°C. Excess SMCC and SPDP were removed using a PD-10 column (Amersham Pharmacia, Tokyo, Japan). Truncated PEA coupled with SPDP was activated with tris(2-carboxyethyl)phosphine (Molecular Probes, Eugene, OR) and mixed with anti-FR␤ mAb–SMCC. This mixture was purified using PD-10, Poros HQ, and TSK 3000 SW columns. Determination of the binding capacity of immunotoxin to the FR␤ antigen. A total of 2 ⫻ 105 FR␤-transfected B300-19 cells, FR␤-transfected B300-19 cells pretreated with 2668 NAGAYOSHI ET AL Figure 1. Reactivity of anti–folate receptor ␤ (FR␤) monoclonal antibody (mAb). A, In these studies, a, FR␤-transfected B300-19 cells, b, B300-19 cells, and d, KB nasopharyngeal epidermoid carcinoma cells were reacted with anti-FR␤ mAb, and c, KB nasopharyngeal epidermoid carcinoma cells were reacted with anti-FR␣ mAb. Gray histograms show the control (IgG2a) mAb; black histograms show the anti-FR␤ (36b) or anti-FR␣ mAb. FITC ⫽ fluorescein isothiocyanate. B, FR␤-transfected B300-19 cells, B300-19 cells, and adherent rheumatoid arthritis (RA) synovial mononuclear cells (SMC) were biotinylated, and the lysates were immunoprecipitated with anti-FR␤ mAb 36b (IgG2a isotype; lanes a, c, and e), 94b (IgG1 isotype; lanes b, d, and f), or control antibody (IgG2a [G2a]; lane g). The immunoprecipitates were analyzed on sodium dodecyl sulfate–12% polyacrylamide gels under reducing conditions and detected as described in Materials and Methods. Molecular weight markers are shown at the left. anti-FR␤ mAb (10 g/ml for 15 minutes), or nontransfected B300-19 cells were sequentially incubated with the immunotoxin (1 g/ml) or with the control mAb (1 g/ml) and then with rabbit anti-PEA antibody, followed by fluorescein isothiocyanate–conjugated goat anti-rabbit antibody (Zymed, South San Francisco, CA). Cells were then analyzed by flow cytometry. Adenovirus-mediated FR␤ gene transfer into monocyte/ macrophages. FR␤ cDNA was excised from the pCR2.1 vector by Xba I digestion, blunted using a DNA blunting kit (Takara Shuzo, Kyoto, Japan), and subcloned into the Swa I site of pAxCAwt, which had been generated using an adenovirus expression vector kit (Takara Shuzo). Following the manufacturer’s instructions, human embryonic kidney 293 cells (RIKEN Cell Bank, Tsukuba, Japan) were transfected with this cosmid vector and adenovirus genomic DNA– terminal protein complex to produce replication-incompetent E1- and E3-deficient adenoviruses expressing FR␤. Titers of recombinant adenovirus were determined by plaque assays of 293 cells (26). To obtain high titers of adenovirus, infection of the virus into 293 cells was performed 4 times. The adenoviruses were suspended in culture medium, adjusted to 2 ⫻ 108 plaque-forming units/ml, and stored at –80°C until they were used. Monocyte/macrophages were transfected with the adenovirus as previously described (27). Briefly, monocytes were incubated with 20 ng/ml of M-CSF for 24 hours, transfected with the adenovirus vector at a multiplicity of infection of 50, and centrifuged at 2,000g for 2 hours at 37°C. Measurement of apoptotic cells. FR␤-expressing B300-19 cells (2 ⫻ 105/ml), B300-19 cells (2 ⫻ 105/ml), macrophages (1 ⫻ 106/ml), adherent RA synovial mononuclear cells (1 ⫻ 106/ml), and adherent lung mononuclear cells (1 ⫻ 106/ml) in DMEM (Nikken, Kyoto, Japan) contain- TARGETING OF RA SYNOVIAL MONONUCLEAR CELLS WITH ANTI-FR␤ AND TRUNCATED PEA 2669 Figure 2. Distribution of folate receptor ␤ (FR␤)–expressing cells in rheumatoid arthritis synovial tissues. Cryosectioned synovial tissues were stained with A, Alexa Fluor 488–conjugated anti-CD163 monoclonal antibody (mAb) (green), B, biotinylated anti-FR␤ mAb (red), or C, both of these mAb (yellow), followed by rhodamine–avidin D. Sections were examined by confocal laser microscopy. LL ⫽ lining layer; SL ⫽ sublining layer. ing 10% human AB serum were placed into 24-well plates and incubated at 37°C in an atmosphere of 5% CO2 for various times (see below) in the presence of either immunotoxin or a mixture of equimolar amounts of anti-FR␤ mAb and truncated PEA at the concentrations indicated below. Propidium iodide (Molecular Probes) staining was performed as described by Nicoletti et al (28). Briefly, cells were stained with propidium iodide (50 g/ml) in 0.1% sodium citrate plus 0.1% Triton X-100 for 20 minutes at 4°C. Apoptotic cells were detected by flow cytometry. Immunoprecipitation and Western blot analyses. FR␤-expressing B300-19 cells, B300-19 cells, and adherent RA synovial mononuclear cells were biotinylated with Sulfo-NHSLC-Biotin (Pierce) and lysed in buffer containing 1% Triton X and proteinase inhibitors. The lysates were immunoprecipitated with either anti-FR␤ mAb or control mAb bound to protein G–agarose (Santa Cruz Biotechnology, Santa Cruz, CA). The immunoprecipitates were run on sodium dodecyl sulfate (SDS)–polyacrylamide 12% gels under reducing conditions, transferred to Hybond ECL nitrocellulose membranes (Amersham Pharmacia), and stained with streptavidin– peroxidase (Zymed). The membranes were incubated in enhanced chemiluminescent reagents (Amersham Pharmacia). Chemiluminescence was detected on Hyperfilm ECL (Amersham Pharmacia). The immunotoxin, anti-FR␤ mAb, and truncated PEA were run on SDS–polyacrylamide 10% gels under reducing conditions, transferred to Hybond ECL nitrocellulose membranes, and reacted with rabbit anti-PEA antibody (a gift of Dr. Ira Pastan, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD) and either horseradish peroxidase (HRP)–conjugated goat anti-rabbit antibody or HRP-conjugated goat anti-mouse IgG antibody (both from Bio-Rad, Hercules, CA). The blots were then developed as described above. Immunohistochemical analysis. Serial frozen sections were stained using biotinylated anti-FR␤ mAb or biotinylated anti-CD163 mAb (Maine Biotechnology Service, Portland, ME), streptavidin–peroxidase, and aminoethylcarbazole reagent (Nichirei, Tokyo, Japan). Cryosectioned RA synovial tissues were stained using biotinylated anti-FR␤ mAb followed by rhodamine–avidin D (Vector, Burlingame, CA) and Alexa Fluor 488–conjugated anti-CD163 mAb (Molecular Probes). Double-stained sections were imaged by confocal laser microscopy (Leica Microsystems, Wetzlar, Germany) using a 488-nm argon ion laser and a band-pass 515–545-nm emission filter for Alexa Fluor 488 and a 568-nm argon ion laser and a band-pass 570–630-nm emission filter for rhodamine. Large field of view images were acquired using a 20⫻ objective lens with detector pinholes completely opened to give pseudoconventional images. The resulting images were 12 bit, and 1,024 ⫻ 1,024 pixels, giving a pixel resolution of 0.45 m pixel size. Contrast and brightness were set using bright samples to ensure that there was no saturation of the pixels. Measurement of TNF␣ production by adherent RA synovial mononuclear cells. RA synovial mononuclear cells (1 ⫻ 106/ml) were suspended in DMEM containing 10% human AB serum, placed in 24-well plates with either the immunotoxin or a mixture of equimolar amounts of antiFR␤ mAb and truncated PEA, and incubated for 12 hours at 37°C in an atmosphere of 5% CO2. After 2 washes with phosphate buffered saline, the cells were incubated for 12 hours with 10 g/ml of LPS. TNF␣ in culture supernatants was measured in duplicate by an enzyme-linked immunosorbent assay using an anti-TNF␣ antibody and a biotinylated antiTNF␣ antibody according to the manufacturer’s protocol (Pierce). Serial dilutions of recombinant TNF␣ (Pierce) were used as the standard for the determination of TNF␣ concentrations. 2670 NAGAYOSHI ET AL Figure 3. Characterization of the immunotoxin composed of anti–folate receptor ␤ (antiFR␤) monoclonal antibody (mAb) and truncated Pseudomonas exotoxin A (PEA). A, The immunotoxin (lane a), anti-FR␤ mAb (lane b), and truncated PEA (lane c) were transferred by Western blotting and were reacted with anti-PEA antibody (anti-PE) or anti-mouse IgG antibody (anti-mouse Ig) as described in Materials and Methods. Arrowheads show the bands reacting with both the anti-PEA antibody and the anti-mouse IgG antibody. Molecular weight markers are shown at the left. B, To examine the binding of the immunotoxin to the FR␤ antigen, a, FR␤-transfected B300-19 cells, b, FR␤-transfected B300-19 cells pretreated with anti-FR␤ antibody, and c, B300-19 cells were reacted with the immunotoxin (black histograms) or with the control antibody (gray histograms) and were then reacted with rabbit anti-PEA antibody, followed by fluorescein isothiocyanate (FITC)– conjugated goat anti-rabbit antibody. Cells were then analyzed by flow cytometry. Statistical analysis. The nonparametric MannWhitney U test was used to test for differences. P values less than 0.05 were considered significant. RESULTS Characterization of FR␤-specific mAb. The 36b and 94b mAb reacted with FR␤-transfected B300-19 cells but not with B300-19 cells or with KB nasopharyngeal epidermoid carcinoma cells expressing the FR␣ antigen (Figure 1A). Moreover, these antibodies immunoprecipitated a 40-kd protein from FR␤-transfected B300-19 cells and adherent RA synovial mononuclear cells (Figure 1B), findings consistent with previously reported results using a polyclonal FR␤-specific mAb (10). We used the mAb to evaluate the expression of FR␤ on peripheral blood leukocytes and in various tissues. The antibodies did not react with freshly ob- TARGETING OF RA SYNOVIAL MONONUCLEAR CELLS WITH ANTI-FR␤ AND TRUNCATED PEA Figure 4. Apoptosis of folate receptor ␤ (FR␤)–transfected B300-19 cells induced by an immunotoxin composed of anti-FR␤ monoclonal antibody (mAb) and truncated Pseudomonas exotoxin A (PEA). FR␤-transfected B300-19 cells (F) or B300-19 cells (E) were cultured in the presence of the indicated concentrations of immunotoxin for 24, 36, or 48 hours. FR␤-transfected B300-19 cells were also cultured in the presence of the indicated concentrations of a mixture of anti-FR␤ mAb and truncated PEA (‚) for 48 hours. The number of apoptotic cells was measured by propidium iodide staining and flow cytometric analysis. Values are the mean ⫾ SEM percentage of apoptotic cells induced by the immunotoxin (n ⫽ 4 experiments). ⴱ ⫽ P ⬍ 0.05 versus B300-19 cells and versus FR␤-transfected B300-19 cells cultured with the mixture of anti-FR␤ mAb and truncated PEA. 2671 tained peripheral blood leukocytes or with monocyte/ macrophages that had been stimulated with LPS, M-CSF, or IFN␥ (data not shown). In contrast, FR␤expressing cells were observed in samples of skin, lung, liver, spleen, kidney, intestine, and lymph node (data not shown), as well as in RA synovium (Figure 2). FR␤ was expressed at high levels in RA synovial tissues and at much lower levels in the other tissues. To determine which cells expressed FR␤, we compared anti-FR␤ mAb–stained sections with serial sections stained with macrophage-specific anti-CD163 mAb. In all tissues, most FR␤⫹ cells also expressed CD163. FR␤-expressing cells in RA synovial tissues were distributed mainly in the sublining layer, while CD163⫹ cells were observed in the lining and sublining layers. Interestingly, alveolar macrophages did not stain with the anti-FR␤ mAb, and Kupffer cells stained weakly with the anti-FR␤ mAb. Effectiveness of the immunotoxin composed of anti-FR␤ mAb and truncated PEA in targeting RA synovial macrophages. This limited distribution of FR␤expressing cells led us to hypothesize that toxinconjugated anti-FR␤ mAb (immunotoxins) would specifically inhibit the activity of RA synovial macrophages and be useful for the treatment of RA. To test this Figure 5. Apoptosis of folate receptor ␤ (FR␤)–transfected macrophages induced by an immunotoxin composed of anti-FR␤ monoclonal antibody (mAb) and truncated Pseudomonas exotoxin A (PEA). A, Macrophages were transfected with an adenovirus vector containing either a, the sense FR␤ gene or b, the antisense FR␤ gene. On day 4 after transfection, macrophages were stained with anti-FR␤ mAb. Gray histograms show the control (IgG2a) mAb; black histograms show the anti-FR␤ mAb. Results are representative of 4 separate experiments using macrophages from different donors. FITC ⫽ fluorescein isothiocyanate. B, On day 1 after transfection, macrophages transfected with the adenovirus vector containing the sense (F) or antisense (E) FR␤ gene were cultured for 3 days in the presence of either the immunotoxin or a mixture of anti-FR␤ antibody and truncated PEA. Apoptotic cells were measured by propidium iodide staining and flow cytometric analysis. The percentage of apoptotic cells in each sample was determined by subtracting the percentage of apoptotic cells induced by the mixture of anti-FR␤ mAb and truncated PEA from that induced by the immunotoxin. Values are the mean ⫾ SEM of 4 separate experiments using macrophages from different donors. ⴱ ⫽ P ⬍ 0.05. 2672 NAGAYOSHI ET AL Figure 6. Apoptosis and inhibition of tumor necrosis factor ␣ (TNF␣) production by adherent rheumatoid arthritis (RA) synovial mononuclear cells induced by the immunotoxin composed of anti–folate receptor ␤ (anti-FR␤) monoclonal antibody (mAb) and truncated Pseudomonas exotoxin A (PEA). A, Adherent RA synovial mononuclear cells (F) or adherent lung mononuclear cells (E) were cultured in the presence of the immunotoxin or a mixture of anti-FR␤ mAb and truncated PEA at an equimolar ratio for 3 days. Apoptotic cells were measured by propidium iodide staining and flow cytometric analysis. The percentage of apoptotic cells in each sample was determined by subtracting the percentage of apoptotic cells induced by the mixture of anti-FR␤ mAb and truncated PEA from that induced by the immunotoxin. Values are the mean ⫾ SEM of 4 separate experiments using different RA synovial tissues and lung tissues. ⴱ ⫽ P ⬍ 0.05. B, Adherent RA synovial mononuclear cells were incubated with various concentrations of immunotoxin (F) or a mixture of anti-FR␤ mAb and truncated PEA (E) at an equimolar ratio for 12 hours. Cells were then stimulated with lipopolysaccharide for 12 hours. Tumor necrosis factor ␣ (TNF␣) in the culture supernatants was measured by enzyme-linked immunosorbent assay. Results are expressed as the percentage of TNF␣ in the absence of the immunotoxin or the mixture of anti-FR␤ antibody and truncated PEA. Values are the mean ⫾ SEM of 4 separate experiments using different adherent RA synovial mononuclear cell preparations. ⴱ ⫽ P ⬍ 0.05. hypothesis, we conjugated an anti-FR␤ mAb (36b) with truncated PEA. Western blot analysis under reducing conditions showed that most of the immunotoxin molecules were of higher molecular weight than the anti-FR␤ mAb heavy chain. Several immunotoxin bands reacted with both anti-PEA antibody and anti-mouse IgG antibody, indicating that the mAb chains were conjugated with truncated PEA (Figure 3A). Furthermore, flow cytometry studies indicated that the immunotoxin bound to the FR␤ antigen (Figure 3B). Specifically, the immunotoxin reacted with FR␤-expressing B300-19 cells but not with B300-19 cells. Moreover, the binding of immunotoxin to FR␤-expressing B300-19 cells was inhibited by an excess of anti-FR␤ mAb. Next, we examined whether the immunotoxin could induce apoptosis of FR␤-expressing cells. As expected, the immunotoxin induced the apoptosis of FR␤-transfected B300-19 cells, but not B300-19 cells. In addition, a mixture of anti-FR␤ mAb and truncated PEA did not induce apoptosis of FR␤-transfected B300-19 cells (Figure 4). These findings indicate the specific effect of the immunotoxin on FR␤-expressing cells. The ability of the immunotoxin to induce apoptosis of FR␤-expressing macrophages was then evaluated. As described above, peripheral blood monocytes and cultured or in vitro–activated macrophages do not express FR␤. Thus, we transfected monocyte/macrophages with a recombinant adenovirus vector encoding the FR␤ gene. The percentages of FR␤-expressing cells after transfection ranged from 30% to 40% (Figure 5A). When the immunotoxin was added to cultures of FR␤expressing macrophages or FR␤-nonexpressing macrophages, the immunotoxin induced significant apoptosis of the FR␤-expressing macrophages as compared with the FR␤-nonexpressing macrophages. However, at the highest concentration tested (5 g/ml), the mixture of anti-FR␤ antibody and truncated PEA induced apoptosis of the FR␤-expressing and FR␤-nonexpressing macrophages (Figure 5B). We then studied the effects of the immunotoxin on RA synovial macrophages. Adherent RA synovial TARGETING OF RA SYNOVIAL MONONUCLEAR CELLS WITH ANTI-FR␤ AND TRUNCATED PEA mononuclear cells contained 40–50% FR␤-expressing cells (or CD14⫹ cells). Many freshly obtained RA synovial macrophages are already apoptotic (29). Thus, the maximum percentage of adherent RA synovial mononuclear cells that could be induced to undergo apoptosis by the immunotoxin would be 40–50%. We found that the immunotoxin induced apoptosis in fewer than 25% of adherent RA synovial mononuclear cells (Figure 6A). In contrast, the immunotoxin did not induce apoptosis in RA synovial fibroblast-like cells from long-term cultures (data not shown). Adherent lung mononuclear cells contain FR␤– alveolar macrophages and FR␤⫹ tissue macrophages. As with adherent RA synovial mononuclear cells, ⬃40– 50% of adherent lung mononuclear cells expressed CD14. We found that the concentration of immunotoxin needed to induce apoptosis of adherent lung mononuclear cells was higher than that needed to induce apoptosis of adherent RA synovial mononuclear cells. These results suggest that RA synovial macrophages are more sensitive to the immunotoxin than are lung macrophages. Next, we examined the effects of the immunotoxin on TNF␣ production by LPS-stimulated adherent RA synovial mononuclear cells. At low concentrations, the immunotoxin significantly inhibited TNF␣ production, as compared with the mixture of anti-FR␤ mAb and truncated PEA (Figure 6B). DISCUSSION We produced 2 mAb that react with FR␤ but not with FR␣. Immunohistochemical analysis revealed FR␤expressing cells in a wide variety of human tissues; most of the FR␤-expressing cells also expressed the macrophage marker CD163. However, FR␤ was not detected on peripheral blood leukocytes, even after in vitro stimulation with LPS, M-CSF, or IFN␥. Previous studies using a polyclonal antibody and Northern blotting techniques indicated that myeloid cells and activated macrophages express FR␤ antigen and mRNA; however, FR␤ on the myeloid cells was not functional (14). It is intriguing that epitopes recognized by our mAb are absent on myeloid cells. This suggests that these epitopes might be associated with the function of FR␤. It has been reported that mice with the Folbp-2 deletion, which is equivalent to FR␤, showed normal growth (30). Furthermore, folic acid has a higher affinity for FR␣ than for FR␤. At present, the physiologic role of FR␤ on hematopoietic cells is not well defined. We recently showed that peroxynitrite generated from nitric oxide and reactive oxide induced the nitration of folic 2673 acid; one of the products, 10-nitro-folic acid, has a higher affinity for FR␤ than for FR␣ (31). These findings, combined with those from the current study, suggest that FR␤ on tissue macrophages might be required for the incorporation of folate derivatives for the synthesis of proinflammatory proteins. We found FR␤-expressing macrophages in the sublining layer of RA synovial tissues. In a previous study by Cauli et al (32), many 27E10⫹ early macrophages were found in the sublining layer, whereas 25F9⫹ mature macrophages were more abundant in the lining layers. Thus, the majority of FR␤-expressing macrophages in RA synovial tissues seem to be acute inflammatory macrophages. Further examinations using various pathologic tissues should help to clarify the nature of FR␤-expressing macrophages. There are several reports about folate-containing reagents that target FR␤-expressing leukemia cells and macrophages (33,34). However, folic acid binds more avidly to FR␣ than to FR␤. In addition, cells have routes for folic acid uptake other than via folate receptors. Thus, reagents with higher affinity for FR␤ than for FR␣ should be used for targeting FR␤-expressing cells. Anti-FR␤ mAb has many advantages over other methods of drug delivery via FR␤ in terms of specificity. In the present study, we produced an immunotoxin composed of an anti-FR␤ mAb and a truncated PEA (LysPE38QQR), which lacks the cell-binding domain but retains the translocation and the adenosine diphosphate ribosylation domains (24). After internalization and proteolytic processing, domain II functions to translocate the toxin to the cytosol; the domain catalytically ADP-ribosylates elongation factor 2 in the cytosol, leading to the arrest of protein synthesis and the induction of apoptosis (16,17). Although most malignant cells are actively proliferating, RA synovial macrophages in the cultures we used are nondividing. We assumed that monocyte/macrophages might be resistant to PEA, as compared with dividing tumor cells. However, in the present culture system, our immunotoxin induced apoptosis and inhibited the production of TNF␣ by adherent RA synovial mononuclear cells. FR␤ was found only on macrophages in the adherent RA synovial mononuclear cell cultures. Moreover, macrophages are the main producers of TNF␣ in adherent RA synovial mononuclear cell cultures (1,2). The immunotoxin did not induce apoptosis of cultured RA synovial fibroblast-like cells. Taken together, these findings support the notion that the immunotoxin mainly damaged RA synovial macrophages. The action of the immunotoxin is not mediated 2674 NAGAYOSHI ET AL through macrophages Fc␥ receptors, since the immunotoxin induced more apoptosis of the FR␤ gene– transfected macrophages than of the antisense gene– transfected macrophages. The data from the present study suggest that the immunotoxin might ameliorate joint inflammation in patients with RA by inhibiting the activity of synovial macrophages. However, improvements in the immunotoxin, such as using recombinant monomeric or dimeric Fv immunotoxins, would cause less immunogenicity and more accessibility to lesions (35,36). The toxic side effects of immunotoxins are of at least 2 types. One type results from damage to normal cells that express the target antigen. Another type is nonspecific and is usually characterized by damage to liver cells (37). A recent study indicated that an antiCD64 mAb conjugated with ricin A induced apoptosis of RA synovial fluid macrophages and inhibited the production of TNF␣ and interleukin-1␤ in synovial tissue explants (20). However, the CD64 antigen is expressed on monocytes and activated neutrophils in addition to tissue macrophages. Thus, immunotoxins using an antiFR␤ mAb have advantages over those using an antiCD64 mAb because of the limited distribution of FR␤ and the low levels of FR␤ expression in normal tissues (38). Severe systemic toxicity might be observed with the in vivo use of immunotoxins. Thus, we would prefer to develop strategies to target activated macrophages in the joints by local injections of the immunotoxin during the first clinical trial. We have recently observed that our immunotoxin inhibited the growth of FR␤-expressing HL-60 cells (promyelocytic leukemia cells) implanted in SCID mice (Nagayoshi R, et al: unpublished observations). In addition to reducing the activity of RA and FR␤-expressing leukemias, the immunotoxin should reduce the activity of other diseases in which macrophage activation is involved in the pathogenesis (39). ACKNOWLEDGMENTS The authors would like to thank Dr. Ira Pastan (Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD) and Dr. S. A. Michie (Department of Pathology, Stanford University School of Medicine, Palo Alto, CA) for critical review of the manuscript. REFERENCES 1. Mulherin D, FitzGerald O, Bresnihan B. Synovial tissue macrophage population and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115–24. 2. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189–202. 3. Liu H, Pope RM. Phagocytes: mechanisms of inflammation and tissue destruction. Rheum Dis Clin North Am 2004;30:19–39. 4. Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 1999;38:818–25. 5. Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, et al. Synovial macrophage depletion with clodronatecontaining liposomes in rheumatoid arthritis. Arthritis Rheum 2000;43:1951–9. 6. Bondeson J. The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol 1997;29:127–50. 7. Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology (Oxford) 2001;40:367–74. 8. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF␣ monoclonal cA2 binds recombinant transmembrane TNF␣ and activates immune effector functions. Cytokine 1995;7:251–9. 9. Feldmann M, Elliot MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-␣ therapy of rheumatoid arthritis. Adv Immunol 1997;64:283–350. 10. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, et al. Selective expression of folate receptor ␤ and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999;42: 1609–16. 11. Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, Grote LA, et al. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 2002;46:1947–55. 12. Nagayoshi R, Nakamura M, Ijiri K, Yoshida H, Komiya S, Matsuyama T. Ly309887, antifolate via the folate receptor suppresses murine type collagen II-induced arthritis. Clin Exp Rheumatol 2003;21:719–25. 13. Ross JF, Wang H, Behm FG, Mathew P, Wu M, Booth R, et al. Folate receptor type ␤ is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999;85: 348–57. 14. Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, Low PS. Expression and functional characterization of the ␤-isoform of the folate receptor on CD34⫹ cells. Blood 1999;93:3940–8. 15. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor ␤-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002;100: 594–602. 16. Kreitman RJ. Chimeric fusion protein-Pseudomonas exotoxinbased. Curr Opin Investig Drugs 2001;2:1282–93. 17. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003:52:338–41. 18. Thepen T, van Vuuren AJ, Kiekens RC, Damen CA, Vooijs WC, van de Winkel JG. Resolution of cutaneous inflammation after local elimination of macrophages. Nat Biotechnol 2000;18:48–51. 19. Bruhl H, Cihak J, Stangassinger M, Schlondorff D, Mack M. Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV. J Immunol 2001;166:2420–6. 20. Van Roon JA, van Vuuren AJ, Wijngaarden S, Jacobs KM, Bijlsma JW, Lafeber FP, et al. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fc␥ TARGETING OF RA SYNOVIAL MONONUCLEAR CELLS WITH ANTI-FR␤ AND TRUNCATED PEA 21. 22. 23. 24. 25. 26. 27. 28. receptor I–directed immunotoxin. Arthritis Rheum 2003;48: 1229–38. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24. Matsuyama T, Nakashima N, Matsuda T, Nakamura H, Uchida S, Abe T. Induction of multinucleated giant cells from rheumatoid arthritis (RA) synovial adherent cells by anti-DR antibody. Clin Exp Immunol 1994;98:257–63. Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990;18:5322. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000;23: 473–9. Carroll SF, Collier R. Active site of Pseudomonas aeruginosa exotoxin A: glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem 1987;262:8707–11. Graham FL, Prevec L. Manipulation on adenovirus vectors. In: Murray EJ, editor. Gene transfer and expression protocols: methods in molecular biology. Vol. 7. Clifton (NJ): The Humana Press; 1991. p. 109–28. Mayne GC, Borowicz RA, Greeneklee KV, Finlay-Jones JJ, Williams KA, Hart PH. Centrifugation facilitates transduction of green fluorescent protein in human monocytes and macrophages by adenovirus at low multiplicity of infection. J Immunol Methods 2003;278:45–56. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271–9. 2675 29. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995;96:1631–8. 30. Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA, Richardson J, et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 1999;23:228–32. 31. Nakamura M, Nagayoshi R, Ijiri K, Nakashima-Matsushita N, Takeuchi T, Matsuyama T. Nitration and chlorination of folic acid by peroxynitrite and hypochlorous acid, and the selective binding of 10-nitro-folate to folate receptor ␤. Biochem Biophys Res Commun 2002;297:1238–44. 32. Cauli A, Yanni G, Panayi GS. Interleukin-1, interleukin-1 receptor antagonist and macrophage populations in rheumatoid arthritis synovial membrane. Br J Rheumatol 1997;36:935–40. 33. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067–84. 34. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127–41. 35. Nagata S, Onda M, Numata Y, Santora K, Beers R, Kreitman RJ, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res 2002;8:2345–55. 36. Onda M, Wang GC, Guo HF, Cheung NK, Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004;64:1419–24. 37. Kreitman RJ, Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol 1995;6:297–306. 38. Paulos CM, Turk MJ, Breur GJ, Loe PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004;56: 1205–17. 39. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002;14:548–52.